The market for dermatological drugs is projected to exhibit a robust growth in the future. This is due to increasing prevalence of skin conditions like acne and eczema, the need for novel therapies and the rise in patient awareness of dermatological treatments. The market is also expected to benefit from the introduction of new drugs, as well as from technological advancements in treatment delivery systems. The global market for dermatological drugs was valued at USD 46.9 billion in 2019, and is expected to reach USD 66.2 billion by 2024. The major growth driver in this market is the increased demand for effective and convenient therapies for numerous skin conditions. For instance, there is an increase in the prevalence of atopic dermatitis, often referred to as eczema, which is a chronic skin condition. This is partly attributed to the rise in allergies and increased stress levels. Moreover, the demand for novel therapies, such as topical steroids, combined therapies, and retinoids, is expected to drive the market growth in the forecast period. However, the high cost of treatments, changes in the insurance landscape, and the availability of several over-the-counter drugs act as market restraints for the growth of the global dermatological drugs market. In addition, the stringent regulatory framework is another factor that hinders the market growth. Nevertheless, the overall outlook for the dermatological drugs market looks positive. To stay ahead of the competition, companies are launching novel treatments and tailoring treatments for specific patient groups. For example, minocycline is a widely used antibiotic that shows promising results in the treatment of several skin diseases. The drug has recently been approved by the US Food and Drug Administration (FDA) for treating rosacea. Moreover, the launch of biologic drugs, such as adalimumab, ustekinumab, and etanercept for the treatment of psoriasis, has significantly changed the scene of dermatological drug therapies. These developments assure further growth of the dermatological drug market in the near future.
Title : Paraneoplastic autoimmune multiorgan syndrome or PAMS: Paraneoplastic pemphigus revisited
Sergei A Grando, University of California Irvine, United States
Title : Modern non-invasive methods for in vivo assessment of skin
Georgios N Stamatas, SGS, France
Title : Personalized and precision dermatology through the view of biodesign-inspired translational & data-driven applications: Revolutionary skin treatments for every concern in clinical dermatology integrating skin care experts and consumers
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : The next generation of threads: Lifting, volumization, and biostimulation in one powerful triple action
George Sulamanidze, Plastic Surgeon at Clinic of Plastic and Aesthetic Surgery and Cosmetology TOTALCharm, Georgia
Title : Lymphoproliferative diseases in the practice of a dermatologist
Irina Sergeeva, Novosibirsk State University, Russian Federation
Title : Comparative efficacy of omalizumab and dupilumab in children with Chronic Spontaneous Urticaria (CSU): A retrospective cohort analysis
Molynna Nguyen, University of Toledo, United States
Title : "Mirror mirror on the skin” — A low-cost community strategy to reduce melanoma disparities in Washington, D.C.
Kayla Sampson, Georgetown University School of Medicine, United States
Title : Vitiligo: Not just an aesthetic disorder
Mateja Starbek Zorko, University Medical centre Ljubljana, Slovenia
Title : Personalized and precision medicine as a unique avenue to have the healthcare model renewed to secure the national biosafety: Advanced skincare solutions in individualized cosmetology, reconstructive plastic surgery and the modern beauty
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Keratinocyte apoptosis by caspase – 3 Immunostaining in histopathology as marker of activity as well as correlation with dermoscopy findings in Cutaneous Lupus Erythematosus (CLE) in skin of color: An observational study.
Subhojit Ray, All India Institute of Medical Sciences, India